Immunotherapy is a powerful technique where immune cells are modified to improve cytotoxicity against cancerous cells to treat cancers that do not respond to surgery, chemotherapy, or radiotherapy. Expressing chimeric antigen receptor (CAR) in immune cells, typically T lymphocytes, is a practical modification that drives an immune response against cancerous tissue. CAR-T efficacy is suboptimal in solid tumors due to the tumor microenvironment (TME) that limits T lymphocyte cytotoxicity. In this study, we demonstrate that neutrophils differentiated from human pluripotent stem cells modified with AAVS1-inserted CAR constructs showed a robust cytotoxic effect against prostate-specific membrane antigen (PSMA) expressing LNCaP cells as a model for prostate cancer in vitro . Our results suggest that engineered CAR can significantly enhance the neutrophil anti-tumor effect, providing a new avenue in treating prostate cancers.
Keyphrases
- pluripotent stem cells
- prostate cancer
- induced apoptosis
- radical prostatectomy
- cell cycle arrest
- immune response
- endothelial cells
- squamous cell carcinoma
- early stage
- pet ct
- oxidative stress
- locally advanced
- cell death
- coronary artery disease
- cell proliferation
- radiation induced
- pet imaging
- acute coronary syndrome
- induced pluripotent stem cells
- peripheral blood
- computed tomography
- atrial fibrillation
- wild type
- pi k akt
- surgical site infection